dextromethorphan hydrobromide and quinidine sulfate

FDA Drug Profile — NUEDEXTA, Nuedexta

Drug Details

Generic Name
dextromethorphan hydrobromide and quinidine sulfate
Brand Names
NUEDEXTA, Nuedexta
Application Number
NDA021879
Sponsor
Avanir Pharmaceuticals, Inc.
NDC Codes
3
Dosage Forms
CAPSULE, GELATIN COATED
Routes
ORAL
Active Ingredients
DEXTROMETHORPHAN HYDROBROMIDE, QUINIDINE SULFATE

Indications and Usage

1 INDICATIONS AND USAGE Dextromethorphan hydrobromide and quinidine sulfate capsules are indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Dextromethorphan hydrobromide and quinidine sulfate capsules are a combination product containing dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor) indicated for the treatment of pseudobulbar affect (PBA). ( 1 )